Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review
Open Access
- 1 February 2004
- journal article
- review article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 88 (2), 212-217
- https://doi.org/10.1136/bjo.2003.019471
Abstract
Background: In 2001 the National Institute for Clinical Excellence (NICE) was asked to issue guidance for England and Wales on the use of photodynamic therapy (PDT). This process has been protracted, partly because of a dispute over the magnitude of beneficial effect. This article examines the origins of the debate about the true treatment effect size for PDT with verteporfin. Methods: A systematic review of the clinical effectiveness of PDT compared with current practice was undertaken. Searches in Medline, Embase, the Cochrane Library, and the Internet, updated to January 2003, revealed two fully published and four ongoing randomised controlled trials. Results: The results of the two published trials (TAP and VIP) consistently showed that overall, PDT with verteporfin is more effective than placebo in slowing the rate of vision loss. In the TAP trial, 12 or more subgroup analyses were undertaken on the primary outcome measure and in VIP, 10 subgroup analyses but only on a subset of the trial participants. Subgroup analysis results were found to be inconsistent between the two trials, with VIP suggesting that verteporfin was equally effective in occult as in mixed lesions and TAP suggesting that verteporfin was more effective in the predominantly classic subgroup. Discussion: For several reasons it was considered that the most likely estimate of the predominantly classic subgroup effect size was the whole trial result. This has implications for the relationship between cost and benefit, the subject of intense debate. Results of the ongoing trials should help to clarify this subgroup effect size issue.Keywords
This publication has 16 references indexed in Scilit:
- Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Patients With Age-Related Macular DegenerationAmerican Journal of Ophthalmology, 2002
- EFFECTS OF VERTEPORFIN THERAPY ON CONTRAST SENSITIVITYRetina, 2002
- Verteporfin Therapy for Subfoveal Choroidal Neovascularization in Age-Related Macular DegenerationAmerican Journal of Ophthalmology, 2002
- Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2American Journal of Ophthalmology, 2001
- Extracts from "Clinical Evidence": Age related macular degenerationBMJ, 2000
- Subgroup analysis and other (mis)uses of baseline data in clinical trialsThe Lancet, 2000
- Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With VerteporfinAmerican Journal of Ophthalmology, 1999
- Occult Choroidal NeovascularizationAmerican Journal of Ophthalmology, 1996
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- A Consumer's Guide to Subgroup AnalysesAnnals of Internal Medicine, 1992